Sanofi SA
Closed
SectorHealthcare
86.39 0.51
Overview
Share price change
24h
Min
85.6
Max
86.45
Income | 1.1B 3B |
|---|---|
Sales | 2.9B 15B |
P/E Sector Avg | 25.373 68.089 |
EPS | 3.55 |
Profit margin | 19.832 |
Employees | 74,846 |
EBITDA | 957M 5B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +10.71% upside |
Next Earnings | 28 Jan 2027 |
|---|
Market Cap | 6.1B 103B |
|---|---|
Previous open | 85.88 |
Previous close | 86.39 |
Sanofi SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sanofi SA Forecast
Price Target
By TipRanks
10.71% upside
12 Months Forecast
Average 95.154 EUR 10.71%
High 110 EUR
Low 80 EUR
Based on 14 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sanofi SA
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
